Efficacy of TPI ASM8 During a 14-Day Allergen Challenge

Summary

This is a randomized, double-blind, placebo-controlled, 3-way crossover trial to evaluate the efficacy and safety of two different doses of inhaled TPI ASM8 administered daily for 14 days for the treatment of allergic asthma and allergen-induced asthma.

Timeline

Start

2010-11

Primary completion

2011-12

Completion

2012-02

Drugs

Indications